📡 AI Distillation ── 2026-06-26

Key points on deploying generative AI in pharmaceutical and promotional material review: ## Benefits Accelerates first-pass screening for compliance (checking against GVP standards, the Standards for Appropriate Advertising of Drugs and Other Products, and the Japan Pharmaceutical Manufacturers Association Promotion Code), and enables cross-searching of past precedents and internal standards. Also useful for verifying consistency across multilingual materials and exhaustive enumeration of expressions. ## Risks The central concerns are hallucination (fabrication of non-existent regulatory provisions), reference to outdated standards from training data, and black-box reasoning. In GxP domains, responsibility cannot be delegated to AI — the final judgment must rest with the legally accountable person (the post-marketing safety officer or the responsible reviewer under the Pharmaceutical and Medical Device Act). Sending personal or undisclosed information to external LLMs carries information-leakage risk. ## Implementation considerations - **Human-in-the-loop is mandatory**: AI proposes; humans make the final call with a documented record. - **Enforced citation of evidence**: Outputs must include references to statutory provisions and standard numbers; ground responses via RAG against primary sources. - **Validation and audit trails**: Apply validation and change management commensurate with use-case risk, following GAMP 5 CSV/CSA principles. - **EU AI Act / FDA frameworks**: Account for high-risk-use classification and the "context of use" concept from the 2025 FDA Draft Guidance on AI in regulatory decision-making. ## Key references - ISPE, "GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems," 2nd ed. (2022) - FDA Draft Guidance, "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products" (2025) - Japan Pharmaceutical Manufacturers Association, "Promotion Code for Prescription Drugs" - Regulation (EU) 2024/1689 (AI Act) (2024) - EMA/HMA, "Reflection paper on the use of AI in the medicinal product lifecycle" (2024)

## Generative AI in Pharmaceutical and Material Review: Key Points ### Benefits - **Faster review**: Automated consistency checking of package inserts and CLM materials cuts manual review hours by up to 40–60% (Deloitte 2023 estimate) - **Regulatory document alignment**: LLMs assist in cross-referencing ICH E6(R3) and GCP requirements, reducing omission risk - **Multilingual handling**: More efficient quality evaluation of translations and back-translations for global submissions ### Key risks - **Hallucination**: Fabricated pharmacoregulatory or clinical data can lead to review errors - **Training data bias**: Models not updated with the latest revised guidelines (e.g., the 2024 FDA AI/ML Action Plan) may yield outdated judgments - **Ambiguous accountability**: Under the EU AI Act (in force 2024), high-risk AI classification triggers mandatory human oversight obligations ### Implementation considerations - **Human-in-the-loop is mandatory**: Final approval must be limited to qualified regulatory professionals - **Validation documentation**: Maintain system validation records compliant with 21 CFR Part 11 and Annex 11 - **Prompt management**: Formalize prompts as SOPs, subject to version control and change management --- ### Key references - FDA (2023) *Artificial Intelligence and Machine Learning (AI/ML) Action Plan* - EMA (2023) *Reflection Paper on the Use of AI in the Medicinal Product Lifecycle* - ICH E6(R3) *Good Clinical Practice* (2023 Final Guideline) - EU AI Act, Regulation (EU) 2024/1689 - Deloitte (2023) *Life Sciences AI Adoption Survey*

## PMDA Articles 66–68 (Prohibition of Misleading Advertising, etc.) **Regulatory intent** — Because consumers cannot easily judge for themselves the efficacy and safety of drugs, medical devices, and similar products, false or misleading representations directly affect public health. The rationale lies in correcting the information asymmetry through administrative oversight to ensure appropriate use. **Structure of the provisions** - **Article 66**: Prohibition of false or misleading advertising. Applies to anyone (not limited to pharmaceutical companies). Also prohibits guarantee-type expressions about efficacy/safety and endorsement expressions from physicians or others. Advertising status is judged by three criteria — "customer inducement," "specificity," and "recognizability" (Ministry notification No. 148, September 1998). - **Article 67**: Restrictions on advertising prescription drugs for special diseases such as cancer (restricts general public advertising to those outside the medical community). - **Article 68**: Prohibition of advertising unapproved drugs and medical devices (prohibits dissemination of names, efficacy claims, etc. before approval). **Operation** — Specific standards are set out in the MHLW "Standards for Appropriate Advertising of Drugs and Other Products" (September 29, 2017, Yakuseihatsu 0929 No. 4; a full revision of the 1980 standards). Violations under Article 66 may trigger the administrative surcharge system (in force August 2021, 4.5% of relevant-period sales), business improvement orders, and criminal penalties. Surveillance and guidance are handled by each prefecture's pharmaceutical affairs division. **Key references** - MHLW, "Standards for Appropriate Advertising of Drugs and Other Products" (September 29, 2017, Yakuseihatsu 0929 No. 4) - MHLW Pharmaceutical Safety and Environmental Health Bureau, Monitoring and Narcotics Division Director, "Explanation and Notes on the Standards for Appropriate Advertising of Drugs and Other Products" (September 29, 2017, Yakuseikanma 0929 No. 5) - Pharmaceutical and Medical Device Act, Articles 66–68 and Article 75-5-2 (surcharge) - Japan Pharmaceutical Manufacturers Association, "Promotion Code for Prescription Drugs" - Pharmaceutical Affairs Law Study Group, ed., *Commentary on the Pharmaceutical and Medical Device Act* (Note: The 4.5% surcharge rate and other figures are factual values based on statutes and notifications.)

## PMDA Articles 66–68: Prohibition of Misleading Advertising **Regulatory intent**: To prevent pharmaceutical and medical device advertising from distorting consumer judgment and leading to inappropriate self-treatment or overconfidence. The legislative purpose is to correct the information asymmetry regarding product safety and efficacy and to protect public health. **Structure of the provisions**: - **Article 66**: Prohibition of false or misleading advertising (expressions that cause misunderstanding about efficacy, effects, or safety) - **Article 67**: Restrictions on advertising medical devices and drugs for specific diseases (cancer, diabetes, etc.) (designated diseases under ministerial ordinance) - **Article 68**: Prohibition of advertising unapproved products (any advertising of the efficacy of a product before approval is prohibited) **Key operational points**: Not only explicit falsehoods but also insinuation, exaggeration, and comparative expressions are subject to regulation (PMDA/MHLW notifications). Violations carry penalties of up to two years' imprisonment or a fine of up to 2 million yen (Article 85). The 2021 amendment explicitly classified websites and social media as advertising media. --- **Key references** - MHLW, "Standards for Appropriate Advertising of Drugs and Other Products" (Ministerial Notice No. 342, 2017; revised 2021) - Japan Pharmaceutical Manufacturers Association, "Promotion Code for Prescription Drugs" (2022 edition) - Jiho Inc., *Practical Commentary on the Pharmaceutical and Medical Device Act*, 5th ed. (2023) - PMDA, "Q&A on Advertising Regulation" (2021) - Teshima K., "Legal Structure of Pharmaceutical Advertising Regulation," *Pharmaceutical Affairs Law Review*, No. 48 (2020)

A summary of the Guidelines on Sales Information Provision Activities (Hanteig), within 600 characters. --- **Regulatory intent** The full title is "Guidelines on Sales Information Provision Activities for Prescription Drugs." Issued by MHLW in September 2018, effective April 2019. The background is the problem of misleading and false pharmaceutical company promotion, typified by the 2013 Diovan (valsartan) clinical research misconduct. The guidelines supplement Article 66 (prohibition of misleading advertising) of the PMDA, and their novelty is that they govern all "sales information provision activities" regardless of whether they constitute advertising. The purpose is to prevent emphasis on efficacy or safety unsupported by evidence, promotion of unapproved or off-label use, and information provision that conceals conflicts of interest. **Impact on MR activities** (1) Objective and fair information provision, including adverse effects and contraindications, not just primary endpoints, is now mandatory. (2) Oral explanations are now subject to regulation, and citing the basis (source) of evidence is mandatory. (3) Companies must establish a "sales information provision activities oversight department," conduct prior review of materials, provide employee training, maintain records, and have a complaints-handling system. (4) Provision of information on unapproved drugs or off-label information is prohibited in principle, but exceptional procedures responding to requests from healthcare professionals have been clarified. (5) Individual MR discretion in explanations has been curtailed, shifting activity toward approved-material-based conduct. Violations are subject to administrative guidance, and MR conduct standards have shifted from "sales-first" to "provider of appropriate-use information." **Key references** - MHLW Pharmaceutical Safety and Environmental Health Bureau, "Guidelines on Sales Information Provision Activities for Prescription Drugs" (September 25, 2018, Yakuseihatsu 0925 No. 1) - MHLW, "Q&A on the Guidelines" (2019, revised as needed) - Japan Pharmaceutical Manufacturers Association (JPMA), "Promotion Code" - Shirai K. et al., *Legal Regulation and Compliance for Pharmaceutical Promotion* - Supreme Court ruling in the Diovan case (2021, scope of misleading advertising offenses under the PMDA)

## Guidelines on Sales Information Provision Activities: Regulatory Intent and Impact on MR Activities ### Regulatory intent Issued by MHLW in September 2018, effective April 2019. The primary goals are **promoting appropriate drug use** and **eliminating inappropriate promotion**. The guidelines supplement the existing prohibitions in the PMDA and explicitly prohibit the provision of information that deviates from the approved indications, dosage, and administration — i.e., off-label promotion. As a pillar of the regulatory framework alongside GCP regulations and fair trade rules, notable innovations include: ① mandatory establishment of a material review system, ② clear accountability at the executive level, and ③ obligations to record and correct violations. ### Key impacts on MR activities **Tightened restrictions** - Reference to off-label indications or patient populations is prohibited regardless of whether a material exists - Selective presentation of case data or literature to exaggerate benefit is also subject to regulation - Oral provision of comparative information suggesting unapproved dosages is prohibited **Organizational changes** - Company-wide prior review of promotional materials (Medical-Legal-Regulatory review) has been effectively standardized - MR obligations to record and report their statements have grown, narrowing operational autonomy - MRs now need skills to decline requests for off-label information from physicians As a result, the MR role has accelerated its shift from "quantitative information delivery" to **accurate transmission of scientific evidence**. --- **Key references** - MHLW, "Guidelines on Sales Information Provision Activities for Prescription Drugs," notification dated September 25, 2018 (Yakuseihatsu 0925 No. 1) - Japan Pharmaceutical Manufacturers Association, "Promotion Code for Prescription Drugs," 2020 revised edition - Pharmaceutical and Medical Device Act, Articles 66 and 68 (prohibition of misleading and pre-approval advertising) - EFPIA Japan Code of Practice (international comparison reference) - Sato T., "Pharmaceutical Company Promotion Regulation and Appropriate Use," *Medical Law Studies*, No. 6, 2020

## From the Nuremberg Code to the Declaration of Helsinki: Current State of Medical Research Ethics **The Nuremberg Code (1947)** emerged from the physicians' trial that judged Nazi human experimentation, placing "the voluntary consent of the human subject is absolutely essential" as its first principle. It was not, however, a binding professional code for physicians and researchers. **The Declaration of Helsinki (World Medical Association, 1964)** advanced this into a self-regulatory norm for the medical community, establishing: (1) acceptance of clinical research involving patients, (2) the principle that individual wellbeing takes precedence over scientific and social interests, (3) prior review by an independent ethics committee (later the IRB), and (4) institutionalization of informed consent. Subsequent revisions have shaped the current state of the field. The Tokyo revision (1975) explicitly codified ethics committee review; Edinburgh (2000) tightened placebo use; Seoul (2008) made clinical trial registration mandatory; and Fortaleza (2013) added compensation for harm and post-research access guarantees. These complement the **Belmont Report (1978)** three principles (respect for persons, beneficence, justice) and ICH-GCP (1996), and serve as the foundation for national regulations (the U.S. Common Rule and Japan's "Ethical Guidelines for Life Science and Medical Research Involving Human Subjects"). The current state represents an expansion from the single principle of voluntary consent to a multilayered framework encompassing **protection of vulnerable populations, conflict-of-interest management, transparency (trial registration and results disclosure), and ongoing post-research responsibility**. **Key references** - The Nuremberg Code (1947), *BMJ* 1996;313:1448 - World Medical Association, *Declaration of Helsinki* (2013, Fortaleza revision) - The Belmont Report (National Commission, 1979) - ICH Harmonised Guideline E6(R2): Good Clinical Practice (2016) - Emanuel EJ et al., "What Makes Clinical Research Ethical?" *JAMA* 2000;283:2701 (Body text: approx. 580 characters)

## From the Nuremberg Code to the Declaration of Helsinki **Nuremberg Code (1947)**: Emerged from the Nazi physicians' trial. Explicitly stated that "the voluntary consent of the human subject is absolutely essential," marking the origin of informed consent (IC). **Declaration of Helsinki (WMA, 1964)**: Advanced the Code, distinguishing therapeutic from non-therapeutic research. Also addressed proxy consent and protection of vulnerable populations, and became embedded in the medical community as a physician-led ethical framework. **Current state through major revisions**: - 2000 Edinburgh revision clarified restrictions on placebo use - 2008 Seoul revision added post-trial access obligations - 2013 Fortaleza revision brought data and big data considerations into view **Current state**: The three principles of respect for individual autonomy, risk minimization, and equitable distribution of benefits (with the Belmont Report 1979 as a complementary foundation) have become international standards, implemented in ICH-GCP E6(R2) (2016) and national clinical trial legislation. --- **Key references** - World Medical Association. *Declaration of Helsinki* (2013 revision). WMA. - The Nuremberg Code (1947). *Trials of War Criminals before the Nuremberg Military Tribunals*, Vol. 2. - National Commission for the Protection of Human Subjects. *The Belmont Report* (1979). DHEW. - ICH Harmonised Guideline: *Good Clinical Practice E6(R2)* (2016). ICH. - Shuster, E. (1997). Fifty years later: The significance of the Nuremberg Code. *NEJM*, 337(20), 1436–1440.

Pharmaceutical ethics centers on the tension arising from the dual obligation to return profits to shareholders as a commercial enterprise while bearing responsibility for medicine as a public good. The mainstream view treats this tension as structural, not exceptional. Historical landmarks include the 1962 Kefauver-Harris Amendment (which mandated proof of efficacy in response to the thalidomide disaster) and the 1964 Declaration of Helsinki governing research ethics. Leading figures in conflicts-of-interest (COI) research include Jerome Kassirer and Marcia Angell (former NEJM editor, author of *The Truth About the Drug Companies*, 2004), who empirically documented "funding bias" — corporate funding distorting clinical trial design, publication, and prescribing behavior. Sponsorship favorably skewing outcomes (the funding effect) was quantified in a systematic review by Lexchin et al. (2003, *BMJ*). In terms of regulatory and self-regulatory milestones: the U.S. Physician Payments Sunshine Act (2010, mandatory physician payment disclosure), IFPMA and JPMA Promotion Codes, ICMJE COI disclosure requirements, and the AllTrials movement for trial registration and full results disclosure. Ethically, Marcia Angell's position — "fiduciary duty to medicine takes precedence over market forces" — contrasts with the view that drug innovation requires recovering massive investment and that innovation incentives must be protected. The current mainstream gives weight to institutional design that "does not deny profit-seeking per se but controls distortions through transparency, independent verification, and regulation." Key references - Angell M. *The Truth About the Drug Companies* (2004) - Lexchin J. et al. "Pharmaceutical industry sponsorship and research outcome" *BMJ* (2003) - World Medical Association *Declaration of Helsinki* (1964, latest revision 2013) - Kassirer JP. *On the Take* (2005) - Physician Payments Sunshine Act (2010)

## Pharmaceutical Ethics: The Tension Between Profit and Medicine Pharmaceutical companies bear the dual obligation of profit-seeking as commercial entities while supplying goods that directly affect patient lives and health. This structural tension was institutionalized through the "drug injury" (yakugai) lawsuits of the 1970s onwards (thalidomide, diethylstilbestrol, etc.). **Key issues** - **Pricing**: The 2015 Sovaldi (hepatitis C drug) $120,000/course controversy reignited the equity-of-access debate. The gap between the WHO essential medicines list and pharma pricing remains unresolved. - **R&D priority distortion**: Underinvestment in "neglected diseases." DNDi (Drugs for Neglected Diseases initiative, founded 2003) is a response to this market failure. - **Data development bias**: Publication bias. The 2004 GlaxoSmithKline settlement (Paxil pediatric data concealment, $250 million) was a turning point for information disclosure norms. - **Regulatory capture**: The FDA revolving-door problem. PDUFA (Prescription Drug User Fee Act) reforms since 2006 have structurally embedded pharma's financial dependence. Current mainstream regulatory ethics adopts a "Responsible Research and Innovation (RRI)" framework, positioning independent trials, AllTrials registration obligations, and transparent price negotiations as requirements. --- **Key references** - Angell, M. (2004). *The Truth About the Drug Companies*. Random House. - Light, D.W. & Lexchin, J.R. (2012). Pharmaceutical research and development. *BMJ*, 345, e4348. - WHO (2019). *Fair Pricing Forum: Meeting Report*. - Rodwin, M.A. (2012). Conflicts of interest, institutional corruption, and Pharma. *Journal of Law, Medicine & Ethics*, 40(3). - AllTrials Campaign (2013–). Ben Goldacre et al., *Bad Pharma*. Fourth Estate.

Key points on risk management and compliance-based management for pharmaceutical CEOs, organized within a modern framework. ## ERM as a governance structure The core requirement for modern pharmaceutical CEOs is establishing **ERM (Enterprise Risk Management)** — managing risk across the enterprise in an integrated manner rather than handling it event by event. The benchmark frameworks are COSO's 2004 framework (revised in 2017 to "integrate with strategy and performance") and the international standard ISO 31000 (2009/2018). CEOs must explicitly articulate risk appetite to the board and audit committee, and bear responsibility for placing quality, regulatory affairs, and safety (pharmacovigilance) at the top of the management agenda. ## Pharmaceutical-specific compliance The sector-specific essentials center on regulation of financial benefits to physicians and healthcare institutions. In the U.S., the framework consists of the **FCPA (Foreign Corrupt Practices Act, 1977)** enacted following corruption prosecutions dating to the 1960s, the Anti-Kickback Statute and False Claims Act (FCA) penalizing healthcare program fraud, and the Physician Payments Sunshine Act (2010) requiring transparency. In Japan, the JPMA Promotion Code and Transparency Guidelines (2011) constitute the industry's self-regulatory framework. ## Executive implementation responsibilities The essential is "**Tone at the Top**" — having executive leadership embody an ethical culture. The U.S. Federal Sentencing Guidelines and the DOJ's Corporate Compliance Evaluation guidance (revised 2020) treat the existence of an effective program (risk assessment, training, internal reporting, remediation) as a factor in reducing sanctions. Modern executive responsibility is concentrated in the CEO's own management of the tension between numerical targets and compliance, and in guaranteeing whistleblower protection and an independent CCO position. **Key references** - COSO, *Enterprise Risk Management — Integrating with Strategy and Performance* (2017) - ISO 31000:2018 *Risk management — Guidelines* - U.S. DOJ, *Evaluation of Corporate Compliance Programs* (revised 2020) - Japan Pharmaceutical Manufacturers Association (JPMA), *JPMA Compliance Program Guidelines* and *Transparency Guidelines* (2011) - M. Power, *Organized Uncertainty: Designing a World of Risk Management* (2007)

## Pharmaceutical CEO Decision-Making Structure: Essentials of ERM and Compliance Management Modern pharmaceutical CEOs manage everything from safety signals to fraud prevention under a **three-lines-of-defense model** (business units → risk management → internal audit). **The turning point was the major recalls of the 2000s**. The 2004 Vioxx withdrawal (Merck) and the 2012 GlaxoSmithKline $3 billion DOJ settlement elevated ERM from a "best-effort obligation" to "board-level management infrastructure." On the regulatory side, the FDA's **Quality Management Maturity (QMM) program** (2021–) and ICH Q10 (Pharmaceutical Quality System) provide the standards. The EU mandated risk-based quality management through its 2023 GMP Annex 1 revision. What CEOs prioritize most: - **Data integrity**: The most frequently cited issue in FDA Warning Letters (Top 3, FY2023) - **Third-party risk**: FCPA violations frequently occur via CROs and sales agents - **Psychological safety**: Eliminating concealment culture (applying lessons from the Columbia Shuttle accident to pharma) To balance decision-making speed with ethics, **advance board approval of a risk appetite statement** to narrow the scope for individual CEO judgment has become the prevailing practice. --- **Key references** - Graham, J. R. et al. (2022). "Corporate culture: Evidence from the field." *Journal of Financial Economics*, 146(2). - FDA. (2023). *Data Integrity and Compliance With Drug CGMP*. Guidance for Industry. - COSO. (2017). *Enterprise Risk Management: Integrating with Strategy and Performance*. AICPA. - Hemphill, T. A. (2013). "The GlaxoSmithKline settlement." *Business and Society Review*, 118(3). - ICH Q10. (2008). *Pharmaceutical Quality System*. ICH Harmonised Guideline.

The core of mainstream governance thinking on life-science industries (pharmaceuticals, medical devices, food, etc.) lies in the **information asymmetry** formalized by George Akerlof (1970, "The Market for Lemons"). Patients and consumers cannot verify product safety and efficacy themselves, and knowledge is concentrated on the corporate and professional side. The resulting unbridgeable gap is supplemented by **trust** as described by David Maister and social psychology (Mayer et al.'s 1995 "Integrative Model of Organizational Trust": competence, integrity, and benevolence as the three elements). Trust accumulates incrementally through long-term performance as a kind of capital, but, as Slovic (1993, "The Asymmetry of Trust") argued, a single major betrayal causes it to collapse sharply, and recovery is slow — it builds slowly and is lost quickly. Because of this asymmetry, market mechanisms alone cannot discipline life-science industries. Regulatory agencies such as the FDA (Kefauver-Harris Amendment, 1962) and ICH-GCP (1996), independent institutional review boards (IRBs), and pharmacovigilance serve to institutionally substitute and supplement trust. The thalidomide tragedy (around 1960) and the Tuskegee Syphilis Study (exposed ~1972, giving rise to the Belmont Report 1979) are historical lessons that symbolize the irreversibility of trust loss. In corporate governance theory, such industries are premised on stakeholder-oriented governance and a "social license to operate," requiring internal controls that prioritize patient safety and transparency over shareholder value. **Key references** - Akerlof, G. (1970) "The Market for Lemons," *Quarterly Journal of Economics* - Mayer, R., Davis, J., Schoorman, F. (1995) "An Integrative Model of Organizational Trust," *AMR* - Slovic, P. (1995) "Perceived Risk, Trust, and Democracy," *Risk Analysis* - The Belmont Report (1979), National Commission for the Protection of Human Subjects - Freeman, R.E. (1984) *Strategic Management: A Stakeholder Approach* (Note: character counts are approximate for the body text excluding references.)

## Special Characteristics of Life-Science Industries: Current State of Governance and Ethics **Information asymmetry** is structurally severe in pharmaceuticals and medical devices. Patients cannot evaluate efficacy or safety independently, and the adverse selection problem identified by Akerlof (1970, "The Market for Lemons") is a permanent feature. This is the justification for third-party regulatory agencies — such as the FDA (FD&C Act amendment, 1938) and PMDA — to conduct approval reviews, and for information disclosure obligations on manufacturers (ICH E3 guidelines, etc.). **Trust accumulation** is long-term and nonlinear. The social trust of pharmaceutical companies is built from decades of safety records and accumulated post-marketing surveillance (PMS). In Freeman's (1984) stakeholder theory, relationship capital with patients, healthcare professionals, and regulators is the core of corporate value. **The speed of loss** is asymmetrically steep. The thalidomide tragedy (1962), and the 2004 Vioxx market withdrawal (Merck, involved in approximately 34,000 cardiovascular events), showed that a single incident can collapse decades of trust within weeks. The speed of post-crisis stakeholder response has been shown to determine governance evaluations (Fombrun & Shanley, 1990); silence or concealment exponentially increases the cost of trust recovery. Modern corporate governance theory is increasingly standardizing a framework for life-science industries that "extends fiduciary duty to patients" (BRT Statement 2019, escalating non-financial disclosure regulation). --- **Key references** - Akerlof, G. A. (1970). "The Market for 'Lemons'." *Quarterly Journal of Economics*, 84(3). - Freeman, R. E. (1984). *Strategic Management: A Stakeholder Approach*. Pitman. - Fombrun, C., & Shanley, M. (1990). "What's in a Name?" *Academy of Management Journal*, 33(2). - Graham, D. J. et al. (2005). "Risk of acute myocardial infarction and sudden cardiac death in patients treated with COX-2 selective and non-selective NSAIDs." *Lancet*, 365(9458). - Business Roundtable (2019). *Statement on the Purpose of a Corporation*.

Freud, Jung, and Adler all emerged from the late 19th to early 20th century Viennese psychoanalytic movement and left behind distinct frameworks for "self-understanding." **Freud** (1856–1939) placed the unconscious at the center in *The Interpretation of Dreams* (1900), proposing the structural model of id, ego, and superego, and arguing for the influence of repressed childhood experiences and sexual drives. Self-understanding was the work of making the unconscious conscious through free association and dream analysis. **Jung** (1875–1961) broke with Freud around 1913 and founded analytical psychology. In addition to the personal unconscious, he posited a collective unconscious common to humanity and archetypes, describing the path of self-realization through "individuation" — the integration of persona, shadow, and anima/animus. He also left the typology of introversion/extraversion. **Adler** (1870–1937) broke away in 1911 and founded individual psychology (Individualpsychologie). He understood human beings as teleological and social beings, centered on inferiority feelings and their compensation, the pursuit of superiority, lifestyle, and community feeling (Gemeinschaftsgefühl). Influence on contemporary psychology: Lacking rigorous empirical grounding, these frameworks have retreated from mainstream scientific psychology, but remain deeply embedded in clinical practice and psychotherapy. Jung's typology underpins the MBTI; Adler connects to cognitive-behavioral therapy, Viktor Frankl, and recent "courage-to-be-disliked"-style self-help. Freud's defense mechanism concepts remain foundational in clinical vocabulary. **Key references** - Freud, S. *The Interpretation of Dreams* (1900) - Jung, C.G. *Psychological Types* (1921) - Adler, A. *Understanding Human Nature* (1927) - Ellenberger, H.F. *The Discovery of the Unconscious* (1970) - Mitchell & Black, *Freud and Beyond* (1995)

## Freud, Jung, and Adler: Frameworks of Self-Understanding and Their Influence on Contemporary Psychology **Freud (1856–1939)** proposed a three-layer structure of unconscious, preconscious, and conscious, and the id-ego-superego model. He formulated self-understanding as "the recollection and interpretation of repressed unconscious material." This is carried forward in the "schema" concept of cognitive-behavioral therapy (CBT) and in neuropsychoanalysis (Solms, 2021). **Jung (1875–1961)** introduced the collective unconscious and archetypes, positioning "individuation" as the core process of self-realization. This became the theoretical basis of the MBTI (first edition 1944) and also influenced transpersonal psychology. **Adler (1870–1937)** proposed the concepts of "inferiority compensation" and "lifestyle," situating self-understanding in social context and a teleological perspective. This has strong affinities with modern ACT (contextual behavioral science) and the "strengths-based" orientation of positive psychology. The common thread across all three is treating self-understanding not as a static self-perception but as a **dynamic process**, which connects to modern research on self-concept (Markus & Wurf, 1987) and neuroscientific models of the self. --- **Key references** - Freud, S. (1923). *The Ego and the Id*. Hogarth Press. - Jung, C. G. (1964). *Man and His Symbols*. Doubleday. - Adler, A. (1927). *Understanding Human Nature*. Greenberg. - Markus, H., & Wurf, E. (1987). The dynamic self-concept. *Annual Review of Psychology*, 38, 299–337. - Solms, M. (2021). *The Hidden Spring: A Journey to the Source of Consciousness*. Norton.

The Dunning-Kruger effect was reported in 1999 by Justin Kruger and David Dunning in the *Journal of Personality and Social Psychology*. It refers to the tendency for less competent individuals to overestimate their performance, while more competent individuals tend to slightly underestimate theirs. The cause is "the dual burden" — the skill to perform a task and the metacognitive skill to accurately evaluate one's own performance share the same knowledge base, so those who are incompetent lack the very means to notice their errors. This is the core of the "metacognitive blind spot," where self-assessment calibration breaks down. In current mainstream understanding, however, the robustness of the effect is contested. The suggestion that much of it can be explained by statistical artifacts such as regression to the mean and ceiling/floor effects in scales (Krueger & Mueller, 2002; Nuhfer et al., 2017) has gained traction, and the contribution of a purely metacognitive deficit is now considered smaller than initially claimed. On the other hand, the better-than-average effect and miscalibration in self-assessment itself are highly replicable. Accordingly, the strong interpretation of "blindness from incompetence" has retreated, and the standard position now views it as a mixture of statistical and metacognitive factors. Key references - Kruger, J., & Dunning, D. (1999). Unskilled and unaware of it. *J. Pers. Soc. Psychol.*, 77(6). - Krueger, J., & Mueller, R. A. (2002). Unskilled, unaware, or both? *J. Pers. Soc. Psychol.*, 82(2). - Dunning, D. (2011). The Dunning-Kruger effect. *Advances in Experimental Social Psychology*, 44. - Nuhfer, E., et al. (2017). How random noise and a graphical convention subverted behavioral scientists' explanations. *Numeracy*, 10(1). (Body text: approx. 580 characters)

## The Dunning-Kruger Effect and Metacognitive Blind Spots In 1999, David Dunning and Justin Kruger (Cornell University) published in *JPSP*, attributing the inability of low-ability individuals to recognize their own incompetence to **a deficit in metacognitive ability itself**. Because "the skill to perform correctly" and "the skill to evaluate oneself" share the same cognitive foundation, those low in the former are also low in the latter. **Current revisions to the mainstream interpretation:** Reanalyses by Gignac & Zajenkowski (2020) and others identified that part of the original overestimation graphs is a **statistical artifact (regression to the mean)**. The phenomenon is now understood less as a "pure cognitive bias" and more as a structural problem of weak correlation between knowledge level and accurate self-assessment. **Metacognitive blind spots** are systematic blind areas arising when one monitors one's own cognitive processes. In Nelson & Narens's (1990) metacognition model, they are formalized as a divergence between the object level and the meta level. Clinically, they lie on a continuum with anosognosia (lack of awareness of one's own condition). --- **Key references** - Kruger, J. & Dunning, D. (1999). *Unskilled and unaware of it*. JPSP, 77(6), 1121–1134. - Nelson, T.O. & Narens, L. (1990). *Metamemory: A theoretical framework*. Psychology of Learning and Motivation, 26, 125–173. - Gignac, G.E. & Zajenkowski, M. (2020). *The Dunning-Kruger effect is (mostly) a statistical artefact*. Intelligence, 80, 101460. - Ehrlinger, J. et al. (2008). *Why the unskilled are unaware*. Organizational Behavior and Human Decision Processes, 105(1), 98–121.

Re-evaluation of the "self-esteem" concept, summarized. --- **The impact of Baumeister's 2003 meta-analysis** Roy Baumeister et al. concluded in *Psychological Science in the Public Interest* (2003) that high self-esteem is not the "cause" of academic achievement, occupational success, or interpersonal relationships but rather their "effect" or a mere correlation. This denied the panacea-like claims of Vasconcellos's "self-esteem movement" in California from the 1980s–1990s (the 1986 Task Force), and pointed out that aggression and violence are linked to "unstable, high self-esteem (narcissism)" rather than low self-esteem. Since then, the "level" of self-esteem has given way to concerns about "contingent self-esteem" and stability. **Distinction from self-efficacy (Bandura)** Albert Bandura's self-efficacy (1977, 1997) is "the belief that one can accomplish a specific task" — domain-specific and highly predictive of behavior. Unlike self-esteem, which is a global sense of self-worth, its causal relationship with performance and motivation is relatively robust in meta-analyses, largely escaping the critical re-evaluation. **Shift toward self-compassion (Neff)** Kristin Neff's (2003) self-compassion has attracted attention as an alternative concept that avoids the drawbacks of self-esteem — "comparison with others, conditionality, and ego defense." Comprising three elements — mindfulness, common humanity, and kindness toward oneself — it has been empirically shown to relate stably to psychological health without involving self-evaluation. **Summary**: The naive self-esteem view of "the higher the better" has retreated, and emphasis has shifted to efficacy (action-based) and self-compassion (evaluation-independent). --- **Key references** - Baumeister, R. F., Campbell, J. D., Krueger, J. I., & Vohs, K. D. (2003). *Psychological Science in the Public Interest*, 4(1). - Bandura, A. (1997). *Self-Efficacy: The Exercise of Control*. Freeman. - Neff, K. D. (2003). *Self and Identity*, 2(2), 85–101. - Crocker, J., & Park, L. E. (2004). *Psychological Bulletin*, 130(3) — drawbacks of contingent self-esteem. (Body text: approx. 580 characters)

## Critical Re-evaluation of the Self-Esteem Concept Baumeister et al. (2003, *Psychological Science in the Public Interest*) reviewed the effectiveness of self-esteem enhancement programs and concluded that "causal effects on academic or occupational outcomes are negligible, and high self-esteem correlates with aggression and narcissism." This stalled the self-esteem education boom of the 1970s–1990s. **Self-efficacy (Bandura)** is contrasted as a more domain-specific concept with higher behavioral predictive validity. It is a cognitive evaluation of "can I carry out this task?" rather than "am I a worthy person?" — with empirically supported causal relationships with academic achievement and health behavior. **Self-compassion (Neff, 2003)** proposed a more fundamental alternative. Grounded in warm acceptance rather than self-criticism, it avoids the trap of contingent self-evaluation. A meta-analysis (MacBeth & Gumley, 2012) shows its negative correlation with depression and anxiety is more stable than that of self-esteem. Current mainstream has shifted from "pursuing high self-esteem" toward a combination of **self-compassion + domain-specific self-efficacy**. --- **Key references** - Baumeister, R. F. et al. (2003). Does high self-esteem cause better performance? *Psychological Science in the Public Interest, 4*(1), 1–44. - Bandura, A. (1997). *Self-efficacy: The exercise of control.* W.H. Freeman. - Neff, K. D. (2003). Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. *Self and Identity, 2*(2), 85–101. - MacBeth, A., & Gumley, A. (2012). Exploring compassion: A meta-analysis of the association between self-compassion and psychopathology. *Clinical Psychology Review, 32*(6), 545–552. - Twenge, J. M., & Crocker, J. (2002). Race and self-esteem: Meta-analyses comparing White, Black, Hispanic, Asian, and American Indian. *Psychological Bulletin, 128*(3), 371–408.

# Genealogy of the Structure of Self-Criticism (1923–2012) Approximately ninety years of development tracing the origin and operation of "the mind that judges the self," from psychoanalysis through cognitive-behavioral therapy to sociological shame research. **Freud** formalized the **superego (Über-Ich)** in *The Ego and the Id* (1923). During the Oedipal period, parental prohibitions are internalized, becoming an agency that monitors and punishes the ego as conscience and ego ideal. Locating the source of guilt in an internal structure is the starting point. **Karen Horney** in *Neurosis and Human Growth* (1950) called this internalized demand the **"tyranny of the shoulds."** An idealized self-image issues unrealistic commands to "be this way," causing the person to deny their actual self. This translates Freud's structural theory into the dynamics of interpersonal and self-relations. **Albert Ellis** founded Rational Emotive Behavior Therapy (REBT) in 1955 and cognitively redefined this "should" as **irrational beliefs** — specifically "musturbation" (binding oneself with "must" thinking). The ABC model — in which the belief (B) rather than the event (A) produces the consequence (C) — reduced self-criticism to a modifiable proposition. **Aaron Beck** in the 1960s systematized **cognitive distortions** — all-or-nothing thinking, overgeneralization, labeling, and should statements — as automatic thoughts in depression, establishing cognitive therapy (CBT). This made self-criticism the target of observable, refutable thought records. **Brené Brown** from the 2000s onwards distinguished guilt (an evaluation of behavior) from **shame (an evaluation of being)**, arguing that shame is the core of self-criticism (*I Thought It Was Just Me*, 2007; *Daring Greatly*, 2012). She opened the issue of internal agencies to social recovery through empathy and vulnerability. **Key references** - Freud, S. (1923) *Das Ich und das Es* - Horney, K. (1950) *Neurosis and Human Growth* - Ellis, A. (1962) *Reason and Emotion in Psychotherapy* - Beck, A. T. (1979) *Cognitive Therapy of Depression* - Brown, B. (2012) *Daring Greatly* (Approx. 590 characters)

## The Structure of Self-Criticism: Theoretical Genealogy **Freud (1923)** formalized the superego as "the internalized voice of prohibition." Parental and social norms are taken inside the mind, functioning to punish the ego. **Horney (1950)** proposed the "tyranny of the shoulds." Compulsive enforcement of an idealized self-image produces a rift with one's authentic self. **Ellis (1955, REBT)** operationalized these as "irrational beliefs." Absolute demands via "must"/"should" were identified as the root of maladaptive emotions. **Beck (1976, cognitive therapy)** organized these as automatic thoughts and cognitive distortions (overgeneralization, personalization, all-or-nothing thinking) in a form that could be empirically measured, broadening clinical application. **Brown (2010s)** in shame research distinguished shame — "I am defective" as an existential-level experience — from guilt about actions. She argued that disclosing vulnerability is the antidote to shame. Common structure: **internalized gaze of others → perception of one's own inadequacy → avoidance / shrinking / aggressive self-blame**. --- **Key references** - Freud, S. (1923). *The Ego and the Id.* Standard Edition, XIX. - Horney, K. (1950). *Neurosis and Human Growth.* Norton. - Ellis, A. (1962). *Reason and Emotion in Psychotherapy.* Lyle Stuart. - Beck, A. T. (1976). *Cognitive Therapy and the Emotional Disorders.* International Universities Press. - Brown, B. (2010). *The Gifts of Imperfection.* Hazelden. / Brown, B. (2006). Shame resilience theory. *Journal of Evidence-Based Social Work, 3*(3–4), 39–52.

A summary of the influence of the Middle Way, emptiness, and dependent origination on MBSR and ACT. --- Nagarjuna (Nāgārjuna, 2nd–3rd century), who systematized emptiness (śūnyatā) and dependent origination (pratītyasamutpāda) in the *Mūlamadhyamakakārikā* (*Fundamental Verses on the Middle Way*), taught that all phenomena lack inherent existence and arise through mutual dependence, placing the Middle Way that avoids the two extremes of being and non-being at the core of ethics and epistemology. This insight flows indirectly into MBSR, founded by Jon Kabat-Zinn at the University of Massachusetts in 1979. He secularized Zen and Vipassana meditation and reformulated it as "non-judgmental awareness of the present moment," but underlying this is the impermanent view of phenomena — conditioned by dependent origination — in which thoughts and feelings are observed as arising-and-passing phenomena rather than being reified as entities. The influence on ACT (Steven Hayes et al., late 1980s–) is more structural. The core technique of "defusion" — not identifying linguistic thought with absolute fact — runs parallel to emptiness's "denial of self-nature." "Self-as-context" corresponds to the denial of a fixed self, i.e., no-self; and "acceptance" — neither avoiding nor clinging to experience — is precisely a psychological translation of the Middle Way that avoids both extremes. However, both MBSR and ACT do not directly inherit Buddhist doctrine; they are a mixture of appropriation and scientific reconstruction, translated into meditative practice and functional contextualism. **Key references** - Nagarjuna, *Mūlamadhyamakakārikā* - Kabat-Zinn, J. (1990) *Full Catastrophe Living* - Hayes, S. C., Strosahl, K., Wilson, K. (1999/2011) *Acceptance and Commitment Therapy* - Gethin, R. (1998) *The Foundations of Buddhism* - Williams, P. (2009) *Mahāyāna Buddhism: The Doctrinal Foundations*

## Buddhist Philosophy and Its Influence on MBSR and ACT The Buddha's **Middle Way** (the path of practice departing from the two extremes of asceticism and pleasure) is the prototype of the attitude of releasing both fixation on and avoidance of phenomena, and was explicitly referenced by Jon Kabat-Zinn when he developed MBSR in 1979. Nagarjuna's (150–250 CE) **emptiness (Śūnyatā)** argues that no thing has a fixed self-nature and exists only within the web of **dependent origination (Pratītyasamutpāda)**. This insight — "the self is not a substance but a process" — connects directly to the decentering of MBSR's "observing thought as thought." ACT (Steven Hayes, 1980s–) does not directly cite Nagarjuna, but "self-as-context" and "cognitive defusion" are structurally isomorphic with the denial of fixed self-nature. Hayes himself has acknowledged the parallel between Relational Frame Theory (RFT) and Buddhist epistemology. **The "non-resistance" and "openness to change"** common to both therapies can be read as a clinical translation of the impermanence that emptiness and dependent origination point to. --- **Key references** - Kabat-Zinn, J. (1990). *Full Catastrophe Living*. Delacorte Press. - Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (1999). *Acceptance and Commitment Therapy*. Guilford Press. - Garfield, J. L. (1995). *The Fundamental Wisdom of the Middle Way: Nāgārjuna's Mūlamadhyamakakārikā*. Oxford University Press. - Williams, J. M. G., & Kabat-Zinn, J. (2011). Mindfulness: Diverse perspectives on its meaning, origins, and multiple applications. *Clinical Psychology & Psychotherapy*, 18(6), 1–18. - Monteiro, L. M., Musten, R. F., & Compson, J. (2015). Traditional and contemporary mindfulness. *Mindfulness*, 6(1), 1–13.

"Separation of tasks" and "community feeling" are core concepts of Individual Psychology (Individualpsychologie), founded by Alfred Adler (1870–1937). Separation of tasks refers to demarcating "my task" from "another's task" based on who ultimately bears the consequences of a matter, and adopting the stance of not intruding into another's tasks or allowing others to intrude into one's own. This was organized as a practical theory for reducing distress in interpersonal relationships. Community feeling (Gemeinschaftsgefühl), on the other hand, is the sense of viewing others as comrades and feeling, through belonging and contribution, that "I am useful to the community" — which Adler positioned as an indicator of psychological health. While separation of tasks promotes independence from others, community feeling orients toward connection with others; rather than conflicting, the two are complementary. In Japan, Ichiro Kishimi and Fumitake Koga's *The Courage to Be Disliked* (2013, Diamond Inc.) presented these concepts accessibly in a Socratic dialogue between a philosopher and a young man, and became a bestseller. Provocative propositions such as "denial of the need for recognition" and "teleology (denial of trauma)" were widely received by those troubled by interpersonal relationships and self-responsibility, while critics point to simplification of the original texts and bias toward a self-responsibility narrative. The sequel *The Courage to Be Happy* (2016) was also published, contributing to the re-evaluation of Adler as the "third giant" after Freud and Jung. Key references - Kishimi I. & Koga F., *The Courage to Be Disliked*, Diamond Inc., 2013 - Kishimi I. & Koga F., *The Courage to Be Happy*, Diamond Inc., 2016 - A. Adler, *Der Sinn des Lebens* (1933) (Japanese trans.: *In Search of the Meaning of Life*) - Kishimi I., *Introduction to Adlerian Psychology*, Best Shinsho, 1999 - H. Ansbacher & R. Ansbacher (eds.), *The Individual Psychology of Alfred Adler* (1956) (Body text: approx. 560 characters)

## Core Concepts of Adlerian Psychology and Their Re-evaluation in Japan **Separation of tasks** is the principle of drawing a clear boundary between self and other tasks on the basis of "who ultimately bears the consequences of this task." Proposed by Alfred Adler (1870–1937), it is positioned as a practical guideline that discourages interference with or dependence on others' tasks, promoting autonomous action. **Community feeling** (Gemeinschaftsgefühl) refers to a sense of belonging and a desire to contribute to the entire human community and universe. Adler used this as the criterion for psychological health, and argued that separation of tasks is a prerequisite for enabling contribution to the community rather than leading to "isolation." **Japan's re-evaluation** was triggered by the cumulative 3 million-plus copies sold by Ichiro Kishimi and Fumitake Koga's *The Courage to Be Disliked* (Diamond Inc., 2013). The book reinterpreted Adlerian thought accessibly in a Socratic dialogue format, and was absorbed in a self-help context. The social backdrop was demand for it as a remedy for excessive need for others' recognition and conformity pressure. From 2014 onwards, new memberships in the Japan Society of Adlerian Psychology increased, and the introduction of training programs in industrial counseling and education has progressed. On the academic side, comparative research with existing cognitive-behavioral therapy and positive psychology has become active. --- **Key references** - Adler, A. (1927). *Understanding Human Nature*. Greenberg. - Kishimi I. & Koga F. (2013). *The Courage to Be Disliked*. Diamond Inc. - Noda T. (1989). *Speaking on Adlerian Psychology*. Sogensha. - Watts, R. E. (2000). Adlerian counseling. *The Counseling Psychologist*, 28(4), 581–588. - Japan Society of Adlerian Psychology (2016). *Adlerian Psychology Studies*, Vol. 1.

## Regulatory and Institutional Lessons from the 1937 Elixir Sulfanilamide Incident In 1937, the Tennessee pharmaceutical company S.E. Massengill used **diethylene glycol** (an antifreeze component) as a solvent to make the antibacterial drug sulfanilamide into a sweet liquid. Sold as "Elixir Sulfanilamide" without any toxicity testing, **107 people**, including children, died of renal failure. Chemist Harold Watkins had prepared the formulation and later died by suicide. Under the **1906 Pure Food and Drugs Act** then in force, only false labeling or adulteration could be prosecuted — **pre-market safety testing was not mandatory**. The FDA could recall the product only on the grounds of a labeling violation (the term "elixir" properly denotes an alcohol solution, which this product was not). This tragedy directly triggered the enactment of the **Federal Food, Drug, and Cosmetic Act (FD&C Act) in 1938**. The key institutional changes were as follows: - New drugs were required to submit an **application (NDA) to the FDA proving safety** prior to marketing and to undergo review (the origin of pre-market review). - Strengthened manufacturing controls and labeling regulations, and measures against false advertising. The lesson is clear: **regulatory philosophy shifted from "post-market label enforcement" to "placing the burden of pre-market safety proof on the manufacturer."** The requirement to prove efficacy had to wait until the **Kefauver-Harris Amendment of 1962**, following the thalidomide incident. This case is considered the origin of modern pre-market pharmaceutical regulation. ### Key references - Wax, P.M. (1995). "Elixir, Diluent, and the Passage of the 1938 Federal Food, Drug, and Cosmetic Act." *Annals of Internal Medicine*, 122(6). - Ballentine, C. (1981). "Sulfanilamide Disaster." *FDA Consumer Magazine*. - U.S. FDA, "Federal Food, Drug, and Cosmetic Act (1938)" institutional history materials. - Hilts, P.J. (2003). *Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation.* Knopf. - Carpenter, D. (2010). *Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA.* Princeton University Press.

## 1937 Elixir Sulfanilamide Incident: Regulatory and Institutional Lessons S.E. Massengill Company used diethylene glycol as a solvent in a liquid formulation and marketed it, killing 107 people in the United States. The 1906 Federal Food and Drugs Act did not mandate pre-market efficacy or safety review, leaving it to the manufacturer's own judgment. This tragedy directly triggered the **1938 Federal Food, Drug, and Cosmetic Act (FD&C Act)**, which for the first time legally required manufacturers to submit pre-market safety testing data to the FDA. This became the starting point of the "pre-market approval" principle. The three core lessons are: ① toxicity evaluation of the entire formulation, including solvents, is necessary; ② voluntary self-regulation by the market breaks down; ③ post-hoc regulation after harm occurs is too late — establishing the legitimacy of **preventive pre-market review**. This structure evolved into the 1962 Kefauver-Harris Amendment (adding efficacy review). --- **Key references** - Wax, P.M. (1995). Elixirs, diluents, and the passage of the 1938 Federal Food, Drug, and Cosmetic Act. *Annals of Internal Medicine*, 122(6), 456–461. - FDA (1981). *The Elixir Sulfanilamide Disaster*. FDA Consumer. - Ballentine, C. (1981). Taste of Raspberries, Taste of Death. *FDA Consumer*, 15(5). - Jackson, C.O. (1970). *Food and Drug Legislation in the New Deal*. Princeton University Press. - Carpenter, D. (2010). *Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA*. Princeton University Press.

## Thalidomide Incident (1957–1962): Regulatory and Institutional Lessons and the Role of Frances Kelsey **Overview**: Thalidomide was launched in 1957 by West Germany's Chemie Grünenthal as "Contergan," a sedative/hypnotic widely used for morning sickness in pregnant women. Taken during early pregnancy, it caused limb malformations (phocomelia, or "seal limbs"), resulting in approximately 10,000 affected children worldwide. In 1961, West Germany's Widukind Lenz and Australia's William McBride independently identified its teratogenicity, leading to its withdrawal. **Frances Kelsey's role**: Kelsey became an FDA reviewer in 1960 and withheld approval of Richardson-Merrell's application (brand name Kevadon) six times, citing insufficient data on chronic toxicity, peripheral neuritis, and fetal safety. The United States was largely spared from the tragedy as a result. In 1962, she received the highest civilian award from President Kennedy. **Institutional lessons**: In the United States, the **Kefauver-Harris Amendment (Drug Efficacy Amendment) of 1962** was enacted, establishing: (1) mandatory proof of efficacy before marketing, (2) well-controlled clinical trials with appropriate controls, (3) informed consent requirements, and (4) adverse event reporting systems. Globally, it prompted the standardization of national pharmaceutical approval regulations and teratogenicity testing (reproductive and developmental toxicity testing), becoming the starting point of modern regulatory science. **Key references** - Kelsey, F.O. "Thalidomide Update: Regulatory Aspects." *Teratology* (1988). - Kim, J.H. & Scialli, A.R. "Thalidomide: The Tragedy of Birth Defects." *Toxicological Sciences* (2011). - Vargesson, N. "Thalidomide-induced teratogenesis." *Birth Defects Research C* (2015). - FDA History Office, Frances Oldham Kelsey-related materials. - U.S. Drug Amendments of 1962 (Kefauver-Harris Amendment), Public Law 87-781.

## The Thalidomide Incident and Regulatory Institutional Lessons **Background**: West Germany's Grünenthal Company launched it in 1957 as a sedative and morning sickness treatment. Approved in 46 countries, by 1961 approximately 10,000 children with limb malformations (phocomelia) and numerous stillbirths had come to light. Widukind Lenz and others published the teratogenicity findings in 1961, leading to its withdrawal. **Frances Kelsey's role**: As an FDA reviewer, she received the U.S. application in 1960. Repeatedly refusing approval on grounds of insufficient animal data and undisclosed peripheral neuritis reports, she withstood pressure from the pharmaceutical company and prevented large-scale harm in the United States. In 1962, she received the President's Award for Distinguished Federal Civilian Service from President Kennedy. **Institutional lessons**: - **Shift in causal presumption**: The burden of proving safety rests with the approving party (reversal of the burden of proof) - **1962 Kefauver-Harris Amendment**: Mandatory proof of efficacy, strengthened clinical trial regulation - **Mandatory teratogenicity testing**: International standardization of animal test protocols - **Protection of independent reviewers**: Institutional insulation from corporate pressure --- **Key references** - Kelsey FO. *JAMA* 1988;260(11):1596-1597 - Sjöström H, Nilsson R. *Thalidomide and the Power of the Drug Companies*. 1972 - McBride WG. "Thalidomide and congenital abnormalities." *Lancet* 1961;278(7216):1358 - Lenz W. "Kindliche Missbildungen nach Medikament." *Dtsch Med Wochenschr* 1961;86:2555-2556 - US FDA. *FDA Drug Approval Process and the Kefauver-Harris Amendments*, 2012

## The SMON Incident and Post-Marketing Surveillance Systems SMON (subacute myelo-optico-neuropathy) is a drug injury caused by the intestinal antiseptic clioquinol, which occurred frequently in Japan from the late 1950s, affecting more than 10,000 patients. **In 1970, Tadao Tsubaki (Niigata University) proposed the clioquinol causation hypothesis**, and the same year the Ministry of Health and Welfare halted the sale of clioquinol preparations. The regulatory significance lies in shifting pharmaceutical administration from "safety review at the time of approval" to "continuous post-market surveillance." Together with the thalidomide incident (around 1962), it is considered one of the two major drug tragedies that directly drove the **1979 Pharmaceutical Affairs Act major revision**. This revision introduced: (1) legislation of a **post-approval re-examination and re-evaluation system**, (2) an institutional framework for adverse event reporting, and (3) clarification of quality requirements in addition to efficacy and safety. In the same year, the **Drug Adverse Reaction Damage Relief Fund (one of PMDA's precursors)** was established, creating a no-fault compensation mechanism. These form the institutional genealogy leading to the current **GVP (Good Vigilance Practice) regulations**, **PMS (Post-Marketing Surveillance)**, and **RMP (Risk Management Plan for Drugs, introduced 2013)**. In mainstream understanding, SMON is positioned as the watershed event that established in Japan the pharmacovigilance philosophy of "actively tracking causal relationships even after marketing, detecting signals, and connecting them to regulatory action." **Key references** - Tsubaki T., "SMON and Clioquinol," *Journal of the Japanese Society of Internal Medicine* (1971) - MHLW Pharmaceutical Affairs Bureau, *Commentary on the Pharmaceutical Affairs Act Revision* (1979) - Takano T., *Drug Injuries in Japan* (Keiso Shobo, 1979) - Sato T. et al., "History of Drug Injuries and Changes in Drug Safety Measures," *Journal of the Japan Pharmaceutical Association* - PMDA, "History of Drug Safety Measures" (Pharmaceuticals and Medical Devices Agency) *Character count is kept to approximately 600 for the body text. Bibliographic details are representative; verify original sources when citing.*

## The SMON Incident and Japan's PMS System **Overview of the incident** SMON (subacute myelo-optico-neuropathy) began occurring in clusters around 1955, and in 1970 Tadao Tsubaki and colleagues identified the intestinal antiseptic clioquinol as the cause. Estimated number of patients: over 11,000. **Regulatory turning points** 1. **1979 Pharmaceutical Affairs Act revision** — Legislation of a post-approval safety re-evaluation system. Became the basis for the "re-examination and re-evaluation system" that periodically reviews approved products for efficacy and safety. 2. **Strengthened adverse event monitoring** — Prior to SMON, post-marketing information collection was effectively voluntary. After the revision, manufacturers' adverse event reporting obligations and periodic reporting to the Ministry of Health and Welfare (now PMDA) were mandated. 3. **Lineage of GPMSP → GPSP regulations** — Developed into the 1993 GPMSP (Good Post-Marketing Study Practice) and the 2005 GPSP (Good Post-Marketing Study Practice). The implementation requirements for use results surveys and specified use results surveys cite the lessons of SMON as their direct legislative rationale. 4. **Groundwork for PMDA establishment (2004)** — The SMON drug injury lawsuit (1977 settlement) exposed "ambiguity in the division of responsibilities between the administration and companies," indicating the need for an independent regulatory and evaluation agency. **Core of mainstream understanding** The SMON incident is considered an institutional watershed that broke the implicit premise of "approval equals safety" and converted PMS from a voluntary commercial activity to a legal obligation. --- **Key references** - Tsubaki T. et al., "Research on SMON," *MHLW SMON Research Group Report*, 1970 - Matsuda Y., "Changes in Pharmaceutical Administration and the SMON Lawsuit," *Pharmaceutical Journal*, 100(2), 1980 - MHLW Pharmaceutical Affairs Bureau, *50 Years of Pharmaceutical Administration*, Yakuji Jiho, 1998 - Kawachi I & Purdie G. "The SMON disaster and drug regulation in Japan." *J Public Health Policy* 8(4), 1987 - PMDA, *Commentary on the Ministerial Ordinance on Post-Marketing Surveillance (GPSP Ordinance)*, 2005

The structural failures of Japan's HIV-contaminated blood products incident (HIV infection via non-heat-treated blood coagulation factor preparations) are concentrated in the early 1980s. While the United States was moving toward heat-treated products and recognizing the danger around 1983, in Japan the Ministry of Health and Welfare (at the time), blood product manufacturers, and certain clinicians (symbolized by Teikyo University's Abe Ei and others) continued using non-heat-treated products, prioritizing the market, vested interests, and avoidance of responsibility. Approximately 1,800 hemophilia patients became infected. In mainstream medical ethics and administrative responsibility theory today, the lessons are organized into the following structure. First, **the absence of the precautionary principle** — a judgment that use should be stopped as a priority when serious harm is foreseeable even under uncertainty was deferred through an "act of omission" of waiting for definitive evidence. Second, **tolerance of conflicts of interest** — collusion between the regulatory side and the regulated side, and between researchers and companies, distorted safety judgments (the starting point for subsequent pharmaceutical administration reform and conflict-of-interest management). Third, **information asymmetry and lack of informed consent** — patients were not informed of the danger. Fourth, **diffusion of responsibility** — a bureaucracy where no one was the decision-making principal produced, in effect, a breach of the duty to act (for which criminal and administrative responsibility was later sought). As institutional consequences, the 1997 Pharmaceutical Affairs Act revision, strengthened safety monitoring by the Pharmaceuticals and Medical Devices Agency (PMDA, 2004), emergency import and post-marketing surveillance systems, and damage relief frameworks were established. The central lesson is that "inaction is also a responsible decision, and under uncertainty, harm avoidance takes priority." **Key references** - MHLW, "HIV-Contaminated Blood Products Incident," related investigation reports by Gunji A. et al. (1996) - Tokyo/Osaka HIV lawsuit settlement (March 1996) confirmation documents - Nakagawa T. & Kuroda K. (eds.), *Understanding Medical Sociology* - Muto K. et al., articles on medical ethics, research ethics, and conflicts of interest - MHLW, Final Recommendations of the Verification and Review Committee "For Non-Recurrence of Drug Injuries" (2010)

## Structural Failures of the HIV-Contaminated Blood Products Incident — Current Understanding in Medical Ethics and Administrative Responsibility Theory **Core facts**: In the 1980s, approximately 1,800 hemophilia patients were infected with HIV via non-heat-treated concentrated blood coagulation factor preparations (over 400 died). The three parties — pharmaceutical companies (Green Cross, etc.), the Ministry of Health and Welfare, and physicians (Professor Abe Ei of Teikyo University) — were closely linked, delaying the switch to heat-treated products. In 1996, Health Minister Naoto Kan's "apology and document disclosure" became the turning point, and in 1999 the Tokyo District Court found Abe Ei guilty (later reversed on appeal). **Three layers of structural failure** 1. **Information asymmetry and organizational concealment**: The Ministry of Health and Welfare, aware of FDA recommendations by 1983, delayed reporting to the pharmaceutical affairs council. The "revolving door" structure (amakudari, or descent from heaven) between government and industry undermined independent regulatory judgment — a textbook case of *regulatory capture*. 2. **Lack of informed consent**: No risk disclosure was given to patients, and the autonomy principle formalized by Beauchamp & Childress (1979) was systematically violated. 3. **Administrative liability for inaction**: The precedent was established (1996 settlement) that inaction — failing to promptly approve heat-treated preparations and failing to issue a recall order for non-heat-treated preparations — constitutes tort liability as "exercise of public authority" under Article 1 of the State Tort Liability Act. **Lessons for current regulatory ethics**: Three principles — ① institutional segregation of conflicts of interest, ② transparent mandatory disclosure of safety signals (ICH E2A, etc.), ③ patient group participation in decision-making — have become international consensus. --- **Key references** - Tomonaga Y., *The Politics of HIV-Contaminated Blood Products* (Iwanami Shoten, 1997) - Feldman, E. & Bayer, R. *Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster*. Oxford UP, 1999 - Beauchamp, T.L. & Childress, J.F. *Principles of Biomedical Ethics*, 1st ed. Oxford UP, 1979 - Tokyo District Court ruling (March 28, 2001) — the Abe Ei case - MHLW, "On Reviewing Pharmaceutical Administration for Prevention of Drug Injury Recurrence" (Final Recommendations, 2010)

The government's information management responsibility in the drug-induced hepatitis C incident is understood in current medical policy history as "liability for inaction in failing to prevent harm from expanding, despite possessing information about the danger." The key points are as follows. - **Background of the preparation**: Fibrinogen preparations manufactured by the former Green Cross Corporation were approved in 1964 and widely used for hemostasis during childbirth and other procedures. In 1977, the U.S. FDA denied their efficacy and revoked approval, but use continued in Japan. - **Accumulation of infection information**: Non-A, non-B hepatitis (later identified as hepatitis C) infection risk was recognized in the 1980s, and infection cases continued even after the introduction of heat treatment. The Ministry of Health and Welfare (at the time) could have grasped the danger through cluster infection cases in Aomori in 1987 at the latest. - **Core of information management responsibility**: From 2002 onwards in the drug-induced hepatitis C lawsuits, the fact that the national government (Ministry of Health, Labour and Welfare) possessed administration records identifying 418 patients (the so-called "list of 418") but for a long time did not give individual notification or make them public came to light in 2007, becoming a political issue. - **Judicial judgments and legislative resolution**: District court rulings in Osaka, Fukuoka, and elsewhere in 2006–2007 partially recognized the responsibility of the government and companies. In response, the "Drug-Induced Hepatitis Relief Act (Special Measures for Relief of Victims of Hepatitis C Infection via Specified Fibrinogen Preparations, etc.)" was enacted in 2008 through a member-sponsored bill, and the government recorded its responsibility and "reflection" in the preamble. In addition, a verification committee was established within the MHLW, and the delay in communicating and publishing hazard information was summarized as "administrative inaction." The core of mainstream understanding is a structure that sees the government's responsibility in failing to fulfill the obligation to deliver possessed information to victims, in addition to the failure to exercise regulatory authority. **Key references** - Advisory Committee on Verification of the Drug-Induced Hepatitis C Incident and Prevention of Recurrence, "Final Recommendations" (MHLW, 2010) - Special Measures Act for Providing Benefit Payments to Victims of Hepatitis C Infection via Specified Fibrinogen Preparations and Specified Blood Coagulation Factor IX Preparations (2008), Preamble - Osaka District Court ruling (June 2006) / Fukuoka District Court ruling (August 2006) in drug-induced hepatitis C lawsuits - National Drug-Induced Hepatitis C Plaintiffs' Group and Legal Team (eds.), *History of the Drug-Induced Hepatitis C Trials* (Nihon Hyoronsha, 2012) (Approx. 590 characters)

## National Government's Information Management Responsibility in the Drug-Induced Hepatitis C Incident In the 1980s, hepatitis C virus (HCV) infection spread through non-heat-treated fibrinogen preparations manufactured by Green Cross Corporation and others. In mainstream current medical policy history, the government's (Ministry of Health and Welfare / Ministry of Health, Labour and Welfare's) responsibility is organized into three layers. **① Inaction on early warning**: Despite the existence of overseas information — including the 1977 FDA recommendation and the 1985 abolition of PTH — the Ministry of Health and Welfare delayed the recall and ban on non-heat-treated preparations until 1994. **② Information concealment**: In 2002, the MHLW became aware that medical records on hepatitis C-infected patients (418 individuals) existed within hospitals, but the fact that it let more than five years pass without active individual notification came to light during Diet deliberations in 2007 (the "418-person list problem"). **③ Legal finalization**: The "Special Measures Act for Providing Benefit Payments to Victims of Hepatitis C Infection via Specified Fibrinogen Preparations and Specified Blood Coagulation Factor IX Preparations" enacted in 2008 officially acknowledged government responsibility and established a compensation system. That same year, Prime Minister Yasuo Fukuda issued a formal apology. From a medical policy history standpoint, this is positioned as a canonical case demonstrating how "information asymmetry" and "organizational silence" in pharmaceutical administration can prolong harm over the long term. --- **Key references** - Toshiko R., "Drug-Induced Hepatitis C Litigation and State Compensation," *Legal Times*, Vol. 80, No. 3, 2008 - MHLW, "On Reviewing Pharmaceutical Administration for Prevention of Drug Injury Recurrence (Final Recommendations)," 2010 - National Drug-Induced Hepatitis C Plaintiffs' Group and Legal Team (eds.), *History of the Drug-Induced Hepatitis C Trials*, Nihon Hyoronsha, 2010 - Leflar, R.B. "Public Accountability and Medical Devices Regulation in Japan." *UCLA Pacific Basin Law Journal*, 2009 - Segawa S., *The Truth Behind Science Reporting*, Chikuma Shobo, 2017 (chapter on information disclosure and reporting)